21.11.2022 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Dr. Eliav Barr, senior vice president and head of Global Clinical Development, chief medical officer, Merck Research Laboratories, is scheduled to participate .
14.11.2022 - AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval .
The health crisis has particularly hit the response to TB and led countries to fall behind in meeting targets to curb the infectious disease. Merck lifts full-year forecast as Keytruda sales soar Merck & Co on Thursday reported higher-than-expected third-quarter sales and profit on a jump in demand for blockbuster cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil.
18.10.2022 - Merck, (NYSE: MRK), known as MSD outside of the United States and Canada, and the Bill & Melinda Gates Medical Research Institute (Gates MRI) today announced a licensing agreement for two preclinical antibacterial candidates for evaluation as . Seite 1